Insulet (NASDAQ:PODD) will be issuing its quarterly earnings data after the market closes on Wednesday, February 21st. Analysts expect the company to announce earnings of ($0.08) per share for the quarter.
Shares of Insulet (NASDAQ PODD) opened at $72.46 on Wednesday. Insulet has a 1 year low of $38.43 and a 1 year high of $78.65. The stock has a market cap of $4,233.16, a P/E ratio of -144.92 and a beta of 1.59. The company has a debt-to-equity ratio of 4.65, a quick ratio of 4.42 and a current ratio of 4.88.
A number of research firms have weighed in on PODD. Jefferies Group increased their price target on shares of Insulet from $58.00 to $67.00 and gave the stock a “buy” rating in a research note on Friday, November 3rd. Zacks Investment Research downgraded shares of Insulet from a “buy” rating to a “hold” rating in a research note on Saturday, November 11th. Barclays reaffirmed a “buy” rating and set a $78.00 price target on shares of Insulet in a research note on Wednesday, December 13th. BidaskClub downgraded shares of Insulet from a “buy” rating to a “hold” rating in a research note on Saturday, December 2nd. Finally, Raymond James Financial raised shares of Insulet from a “market perform” rating to an “outperform” rating and set a $80.00 price target on the stock in a research note on Monday, January 8th. Eight investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $62.53.
TRADEMARK VIOLATION NOTICE: “Insulet (PODD) Scheduled to Post Quarterly Earnings on Wednesday” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/14/insulet-podd-scheduled-to-post-quarterly-earnings-on-wednesday.html.
Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.